Medications

Diabetologist Amar Puttanna addresses growing concerns about the rise of dementia in diabetes care and highlights where guidelines, research efforts, and management options are needed to tackle this comorbidity.

Ophthalmologist Philip Burgess joins Clinical Diabetologist John Wilding to discuss the treatment of sight-threatening retinopathy and maculopathy in people with diabetes (9:11).

Jay Shubrook comments on the findings of the multinational DUNE study of glycemic target achievement in people with type 2 diabetes taking insulin.

DIY closed-loop insulin delivery has provoked controversy within the diabetes community, raising questions around patient empowerment, safety and liability, and whether the regulatory process remains fit for purpose in a technological age. medwireNews takes a look at the issues.

With the use of insulin pumps and related technologies expected to increase among pregnant women with type 1 diabetes, Pratik Choudhary and Lori Berard discuss management protocols for women admitted to maternity units (4:26).

Pratik Choudhary and Lori Berard discuss considerations for treating diabetes device users admitted for surgical procedures and radiological investigations (11:41).

Lori Berard and Pratik Choudhary address situations that can lead to emergency department admissions in patients using diabetes devices and discuss management strategies tailored to this patient population (9:36).

Lori Berard and Pratik Choudhary address situations that can lead to hospital admissions in insulin pump users, and discuss what the treating clinician needs to know (8:42).

Diabetologist Pratik Choudhary and Nurse Consultant Lori Berard discuss inpatient use of continuous glucose monitoring (CGM) devices and insulin dosing apps (8:14).

Pharmacological management of comorbid cardiovascular risk and type 2 diabetes is undergoing a paradigm shift. General practitioner Kevin Fernando puts recommendations from the ADA/EASD into practice in this patient case study.

Obstructive sleep apnea syndrome is a common and potentially serious comorbidity in people with diabetes and obesity. John Wilding highlights what you need to know about the condition.

John Wilding considers the real-world studies examining the association between SGLT2 inhibitors and amputation risk in patients with type 2 diabetes.

How many real-world studies have looked at amputation risk in users of SGLT2 inhibitors, and do the findings support or refute the effect found in CANVAS? medwireNews rounds up the research so far.

DECLARE-TIMI 58 steering committee member John Wilding talks us through the trial's findings (5:49).

Endocrinologist Sanjay Kalra considers the impact that cardiovascular outcome trials have had on the standard of diabetes care and questions what else they might accomplish in the future.

With DECLARE-TIMI 58 now published, medwireNews rounds up the SGLT2 inhibitor cardiovascular outcome trials so far.

Miles Fisher talks to medwireNews about the results of the dapagliflozin cardiovascular outcomes trial DECLARE-TIMI 58.

This slide set outlines the results of a 10-year, postinterventional follow-up of the UKPDS survivor cohort which examined whether a continued microvascular benefit from earlier improved glucose control was evident and whether such therapy had a long-term effect on macrovascular outcomes.

This slide set outlines the results of the UKPDS33 study which compared the effects of intensive blood-glucose control with either sulfonylurea or insulin and conventional treatment on the risk of microvascular and macrovascular complications in patients with type 2 diabetes.

This slide set outlines the results of the UKPDS34 study which investigated whether intensive glucose control with metformin had any specific advantage or disadvantage in patients with type 2 diabetes.